Effects of methamphetamine on hidden HIV
Part of Infections clinical trials.
This study looks at how a single dose of methamphetamine affects the hidden HIV that stays in the body even when the virus is undetectable. It may help researchers understand how to better treat or cure HIV in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be living with HIV and on a stable HIV medication regimen for at least 12 months.
- Your HIV viral load should be undetectable (below 40 copies/ml) for at least 12 months.
- You should not have a history of methamphetamine use disorder or have used recreational drugs like cocaine or ecstasy recently.
- You must not have certain heart conditions, uncontrolled high blood pressure, or recent serious infections or hospitalizations.
- You must be willing to use two forms of birth control during the study and for up to 90 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of two drugs to see if they can reduce the 'hidden' HIV that stays in your body even when you're on regular HIV treatment. The goal is to work toward a cure, not just control.
This study tests whether giving very high doses of your current HIV meds can flush out hidden HIV that stays in the body even when the virus is undetectable. It might help find a way to reduce or eliminate the reservoir of latent HIV.
This study compares how active the immune system is and how large the “hidden” HIV reservoir is in people on two different HIV treatment types. It may help researchers understand whether staying on a tenofovir-containing regimen leads to better control of HIV hiding in the body.
This trial tests whether psilocybin (a psychedelic medicine) can help people who use methamphetamine and are living with HIV reduce or stop their meth use. You would receive psilocybin in a supervised setting and get counseling support to help you reach your goal of quitting.
This study tests a smartphone program to help HIV-negative men who have sex with men reduce meth use and improve PrEP adherence. It explores whether combining support for both behaviors is more effective than addressing them separately.
This study tests whether a medication called 'Glutide' (a GLP-1 agonist, similar to drugs used for diabetes) can help people who want to stop or cut down on methamphetamine. It's for those with moderate to severe meth use disorder who have used meth on at least 15 of the past 30 days.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.